10x Genomics, Inc. (NASDAQ:TXG) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript February 12, 2025 10x Genomics, Inc. misses on earnings expectations. Reported EPS is $-0.4 ...
GEN4d
Harnessing Single-Cell RNA Sequencing to Study Retinal Ganglion Cell Regeneration in Optic Neuropathies
Single-cell RNA sequencing has established itself as one of the most important technologies for studying the transcriptome of ... Single Cell with the newest 10X Genomics assay on two different ...
eLife3d
Multi-Omics Single-Cell Analysis Reveals Key Regulators of HIV-1 Persistence and Aberrant Host Immune Responses in Early Infection
This study provides evidence that single-cell multi-omics profiling can reveal key regulators of HIV-1 persistence and early immune dysregulation, particularly implicating KLF2 and Th17 cells as major ...
Business Wire17d
Parse Biosciences Invalidates All 10x Genomics’ Patent Claims Asserted Against Its Products
Parse has now invalidated all claims that 10x Genomics asserts against Parse products, further reinforcing Parse’s ability to drive ongoing innovation in the single cell space. In defense of ...
News Medical on MSN8d
Single-cell transcriptome profiling identifies the activation of type I interferon signaling in ossified posterior longitudinal ligament
Ossification of the posterior longitudinal ligament (OPLL) is a progressive spinal disease characterized by ectopic bone ...
Investing10d
Earnings call transcript: 10X Genomics Q4 2024 misses EPS forecast, stock dips
2025 revenue guidance suggests 0-3% growth, with a focus on biopharma and single-cell projects. 10X Genomics experienced a challenging Q4 2024, with revenue declining by 10% year-over-year to $165 ...